Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Antigen-Lipid-Driven Monoclonal Gammopathies
NCT02920190Phase 4Withdrawn
- Sponsor
- University of Miami
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Peptides
01
Overview
A Phase 4 trial of liraglutide in Monoclonal gammopathy (MG), sponsored by University of Miami. Planned start Sep 2020; status: withdrawn.
02
Drugs
03
Conditions
Monoclonal gammopathy (MG)
Beyond the preview
Go deeper on NCT02920190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920190.